OM-RCA-01

In vitro, the combination of nivolumab and OM-RCA-01 resulted in higher levels of interferon gamma and interleukin-2 release compared with nivolumab alone. In vivo, pembrolizumab in combination with OM-RCA-01 produced a greater inhibitory effect on tumor growth compared with vehicle and pembrolizumab alone...Combining an anti-FGFR1 antibody with a checkpoint inhibitor may enhance the efficacy of both drugs. However, further studies are needed to elucidate the mechanism of this interaction.

OM-RCA-01, a anti-FGFR1 humanized antibody, and alofanib, a FGFR2 allosteric inhibitor showed promising results in previous studies...Treatment with ipilimumab (ipi, 200 mcl on days 7, 10, and 13) was initiated in both cohorts when tumor volumes reached 70 mm3...The table summarizes the results of in vivo studies. Table: 1073P Conclusions Inhibition of FGFR1 and FGFR2 following immunotherapy resulted in a twofold suppression of tumor growth, especially in the CAFs+ cohort.

Methods In vitro assays using human T cells were performed to evaluate lymphocyte responses to stimulation with nivolumab alone (1-100 nmol/l) or with OM-RCA-01 (1-10 nmol/l)...Treatment with OM-RCA-01 (30 mg/kg) and pembrolizumab (10 mg/kg) or pembrolizumab alone or saline (vehicle) every 3 days was started when the tumors reached 70 mm3...No group mean body weight losses or clinical manifestations of toxicity were observed. Conclusions Co-inhibition of FGFR1 and PD-1 drives activation of T-cell clones to support enhanced antitumor activity.

Treatment with intravenous OM-RCA-01 (30 mg/kg) with pembrolizumab (10 mg/kg) or pembrolizumab alone (10 mg/kg) or saline (vehicle) every 3 days was started when the tumors reached 70 mm3 in volume. In conclusion, OM-RCA-01 antibody has potent antitumor activity against lung cancer in vitro and in vivo. Our findings also support that the co-inhibition of FGFR1 and immune checkpoints can enhance antitumor activity compared to anti-PD-1 antibody monotherapy.